

**PATIENT PACKAGE INSERT IN ACCORDANCE WITH
THE PHARMACISTS' REGULATIONS (PREPARATIONS) - 1986**

This medicine is dispensed with a doctor's prescription only

Lynparza® 100 mg

Film-coated tablets

Composition:

Each tablet contains:

Olaparib 100 mg

Lynparza® 150 mg

Film-coated tablets

Composition:

Each tablet contains:

Olaparib 150 mg

For inactive ingredients, please see section 6 – "Further Information".

Please see also section 2 – "Important information regarding some of the medicine ingredients".

Read this leaflet carefully in its entirety before using the medicine.

Keep this leaflet. You may need it again.

This leaflet contains concise information about the medicine. If you have any further questions, ask your doctor or pharmacist.

This medicine has been prescribed to treat your ailment. Do not pass it on to others. It may harm them, even if it seems to you that their ailment is similar.

1. WHAT THE MEDICINE INTENDED FOR?

Lynparza is intended:

- Monotherapy, maintenance treatment of adult patients with advanced BRCA1/2-mutated (germline or somatic) high-grade epithelial ovarian (fallopian tube or primary peritoneal) cancer who are in response (complete or partial) to first-line platinum-based chemotherapy.
- Maintenance treatment of patients with platinum-sensitive relapsed high-grade epithelial ovarian (or fallopian tube, or primary peritoneal) cancer who are in response (complete response or partial response) to first-line platinum-based chemotherapy.
- For the treatment of metastatic breast cancer in patients with mutations in BRCA and HER2-negative, who have been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting.
- For the maintenance treatment of adult patients with deleterious or suspected deleterious gBRCAm metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen.
- For the maintenance treatment, in combination with bevacizumab, of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either:
 - a deleterious or suspected deleterious BRCA mutation, and/or
 - genomic instability
- For the treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA1/2 or ATM- mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone.

If you have hormone receptor (HR)-positive disease, the recommendations are treatment with endocrine therapy.

Your physician will perform a test to make sure that Lynparza is right for you.

Lynparza contains the active substance olaparib. Olaparib is a type of cancer medicine called a PARP inhibitor.

PARP inhibitors can trigger the death of cancer cells by blocking an enzyme that helps repair DNA.

Therapeutic group

PARP (poly [adenosine diphosphate-ribose] polymerase) inhibitor.

2. BEFORE USING THE MEDICINE:

X Do not use the medicine if:

- You are sensitive (allergic) to the active ingredient olaparib or any of the other ingredients of this medicine (see section 6 – “Further Information”).
- You are breastfeeding (for additional information, please see section 2 below).

Special warnings regarding use of Lynparza:

I Before or during the course of treatment with Lynparza, tell the doctor if:

- you have low blood-cell counts. These may be low red blood-cell count (anaemia), low white blood-cell count (neutropaenia), or low blood-platelet count (thrombocytopenia).
For further information, see section 4 – “Side Effects”, including the signs and symptoms you need to pay attention to (such as: fever or infection, bruising or bleeding). Rarely, these may be a sign of a more serious problem with the bone marrow such as ‘myelodysplastic syndrome’ (MDS) or ‘acute myeloid leukaemia’ (AML).
- you experience any new or worsening symptoms of shortness of breath, coughing, or wheezing. A small number of patients treated with Lynparza reported inflammation of the lungs (pneumonitis). Pneumonitis is a serious condition that can often require hospital treatment.
- you have any symptoms such as pain or swelling in an extremity, shortness of breath, chest pain, breathing that is more rapid than normal (tachypnea), or heart beats faster than normal (tachycardia). Your healthcare provider will monitor you and may prescribe blood thinner medicine. Some people with prostate cancer who take Lynparza along with gonadotropin-releasing hormone (GnRH) analog

therapy may develop a blood clot in a deep vein, usually in the leg (venous thrombosis) or a clot in the lung (pulmonary embolism).

Tests and checks

Your doctor will refer you for blood tests before and during treatment with Lynparza.

You will perform blood tests in the following manner:

- before treatment
- every month for the first year of treatment
- at regular intervals decided by your doctor after the first year of treatment.

If your blood count falls to a too low level, it may be necessary to have a blood transfusion (where you are given new blood or blood-based products from a donor).

⚠ Drug interaction

If you are taking, or have recently taken, or about to take, other medicines, including non-prescription medicines and nutritional supplements, tell the doctor or pharmacist. Especially if you take:

- any other anticancer medicines.
- a vaccine or a medicine that suppresses the immune system, as you may need to be closely monitored.
- itraconazole, fluconazole - used to treat fungal infections.
- telithromycin, clarithromycin and erythromycin - used to treat bacterial infections.
- protease inhibitors boosted with ritonavir or cobicistat, boceprevir, telaprevir, nevirapine, efavirenz - used to treat viral infections, including HIV.
- rifampicin, rifapentine, rifabutin - used for bacterial infections, including tuberculosis (TB).
- phenytoin, carbamazepine, phenobarbital - used as a sedative or to treat fits (seizures) and epilepsy.
- herbal remedies containing St. John's Wort (*Hypericum perforatum*) - used mainly to treat depression.
- digoxin, diltiazem, furosemide, verapamil, valsartan - used to treat heart conditions or high blood pressure.
- bosentan - used to treat pulmonary artery hypertension.

- statins, for example simvastatin, pravastatin, rosuvastatin - used to lower blood cholesterol levels.
- dabigatran – used to thin the blood.
- glibenclamide, metformin, repaglinide - used to treat diabetes.
- ergot alkaloids - used to treat migraines and headaches.
- fentanyl - used to treat cancer pain.
- pimozide, quetiapine - used to treat mental health problems.
- cisapride - used to treat stomach problems.
- colchicine – used to treat gout.
- cyclosporine, sirolimus, tacrolimus - used to suppress the immune system.
- methotrexate - used to treat cancer, rheumatoid arthritis and psoriasis.
- gonadotropin-releasing hormone (GnRH) analog therapy in addition to Lynparza for prostate cancer - you should continue with this treatment during your treatment with Lynparza unless you have had a surgery to lower the amount of testosterone in your body (surgical castration).

Tell your doctor, pharmacist or nurse if you are taking any of the above or any other medicines. The medicines listed here may not be the only ones that could affect Lynparza.

Use of the medicine and food

Do not drink grapefruit juice while you are being treated with Lynparza. Grapefruit can affect the way Lynparza works.

Pregnancy, breast-feeding and fertility

Women:

- You should not take Lynparza if you are pregnant or might become pregnant, because Lynparza may harm an unborn baby.
- You should avoid becoming pregnant while taking Lynparza. You should use effective methods of contraception while taking Lynparza and for one month after receiving the last dose. It is not known whether Lynparza affects the effectiveness of some oral contraceptives. Please tell your doctor if you are taking an oral contraceptive, as your doctor may add a non-hormonal contraceptive method.

- You should have a pregnancy test before starting Lynparza, at regular times during treatment and one month after receiving the last dose of Lynparza. If you become pregnant during this time, you must talk to your attending doctor straight away.
- It is not known whether Lynparza passes into breast milk. Do not breastfeed if you are taking Lynparza and for one month after receiving the last dose of Lynparza. If you are planning to breastfeed, tell your doctor.

Men:

- You must use a condom when having sex with a female partner, even if she is pregnant, while taking Lynparza and for 3 months after taking the last dose. It is not known whether Lynparza passes into semen.
- Your female partner must also use a suitable method of contraception.
- You must not donate sperm during treatment and for 3 months after taking the last dose.

⚠ Driving and using machines

Lynparza may influence your ability to drive and use machines. If you feel dizzy, weak, or tired while taking Lynparza, do not drive or use tools or machines.

⚠ Important information regarding some of the medicine ingredients

This medicine contains less than 1 mmol sodium (23 mg) per 100 mg or 150 mg tablet, that is to say essentially “sodium-free”.

3. HOW SHOULD YOU USE THE MEDICINE?

Your doctor has prescribed Lynparza **film-coated tablets** for you.

Always take Lynparza according to your doctor’s instructions.

Check with the doctor or pharmacist if you are uncertain about the dosage and manner of treatment with Lynparza.

Do not exceed the recommended dose.

How to take

- **Swallow Lynparza tablets whole, with or without food.**
- Take Lynparza once in the morning and once in the evening.

- Do not chew, crush, dissolve or divide the tablets as this may affect how quickly the medicine gets into your body.

Dosage

- Your doctor will tell you how many tablets of Lynparza to take. It is important that you take the total recommended dose each day. Keep doing so for as long as your doctor, pharmacist or nurse tells you to.
- The usual recommended dose is 300 mg (2 x 150 mg tablets) twice a day - a total of 4 tablets each day.

Your doctor may prescribe a different dose if:

- you have problems with your kidneys. You will be asked to take 200 mg (2 x 100 mg tablets) twice a day – a total of 4 tablets each day.
- you are taking certain medicines that may affect Lynparza (please see section 2).
- you have certain side effects while you are taking Lynparza (please see section 4).
Your doctor may lower your Lynparza dose or stop treatment, either for a short time or permanently.

If you accidentally took a higher dose

If you took an overdose or if a child has accidentally swallowed the medicine, immediately refer to your doctor or to a hospital emergency room and bring the package of the medicine with you.

If you forget to take Lynparza

If you forget to take Lynparza at the scheduled time, do not take a double dose. Take your next normal dose at its scheduled time and consult the doctor.

Continue treatment as recommended by your doctor.

Do not discontinue treatment with Lynparza without consulting your doctor.

Do not take medicines in the dark! Check the label and dose each time you take the medicine. Wear glasses if you need them.

If you have any further questions on the use of this medicine, consult your doctor or pharmacist.

4. SIDE EFFECTS

As with any medicine, use of Lynparza may cause side effects in some users. Do not be alarmed when reading the list of side effects. You may not suffer from any of them.

Side effects that require special attention:

Tell your doctor straight away if you notice any of the following side effects:

Very common side effects (affect more than 1 in every 10 patients):

- **feeling shortness of breath, feeling very tired, having pale skin, or fast heart beat - these may be symptoms of a low red blood cell count (anemia).**

Uncommon side effects (affect up to 1 in every 100 patients):

- allergic reactions (e.g. swelling of the face, lips, tongue or throat, hives, difficulty breathing or swallowing, dizziness which are signs and symptoms of hypersensitivity reactions).
- serious problems with bone marrow (myelodysplastic syndrome (MDS) or acute myeloid leukaemia (AML)). Please see section 2.

Other side effects:

Very common side effects (affect more than 1 in every 10 patients):

- nausea
- vomiting
- feeling tired or weak
- indigestion or heartburn (dyspepsia)
- loss of appetite
- headache
- changes in the way food tastes
- feeling dizzy
- cough
- shortness of breath
- diarrhea. If it gets severe, tell your doctor straight away.

Very common side effects that may show up in blood tests:

- decrease in the number of platelets in blood (thrombocytopenia) - you may notice the following symptoms:
 - bruising or bleeding for longer than usual if you hurt yourself

- low white blood cell count (leukopenia or neutropenia) which may decrease your ability to fight infection and may be associated with fever.

Common side effects (affect 1-10 in every 100 patients):

- rash or itchy rash and swollen, reddened skin (dermatitis)
- sore mouth (stomatitis)
- pain in the stomach area under the ribs (upper abdominal pain).

Common side effects that may show up in blood tests:

- low white blood cell count (lymphopenia) which may decrease your ability to fight infection and may be associated with fever.
- increase in blood creatinine levels - this test is used to check how your kidneys are working.

Uncommon side effects that may show up in blood tests:

- increase in the size of red blood cells (not associated with any symptoms).

Rare side effects (may affect up to 1 in 1,000 patients):

- Painful inflammation of the fatty tissue under the skin (erythema nodosum).

Your doctor will test your blood every month for the first year of treatment and at regular intervals after that. Your doctor will tell you if there are any changes in your blood test that might need treatment.

If a side effect appears, if any of the side effects worsens, or when you suffer from a side effect not mentioned in the leaflet, consult the doctor.

Reporting of side effects

Side effects can be reported to the Ministry of Health by clicking on the link “Report Side Effects of Drug Treatment” found on the Ministry of Health homepage (www.health.gov.il) that directs you to the online form for reporting side effects, or by entering the link:

<https://sideeffects.health.gov.il>

5. HOW TO STORE THE MEDICINE?

- Avoid poisoning! This medicine and any other medicine must be kept in a safe place out of the reach and sight of children and/or infants to avoid poisoning. Do not induce vomiting unless explicitly instructed to do so by the doctor.
- Do not use the medicine after the expiry date (exp. date) that appears on the package. The expiry date refers to the last day of that month.
- Store in the original package to protect from moisture.
- This medicine does not require any special temperature storage conditions. Storage at room temperature is recommended.

6. FURTHER INFORMATION

- In addition to the active ingredient, the medicine also contains:
Copovidone K28, Mannitol, Hypromellose 2910, Silica, colloidal anhydrous, Sodium stearyl fumarate, Titanium dioxide, Macrogol 400, Iron oxide yellow

In addition, Lynparza 150 mg contains:
Iron oxide black

- **What the medicine looks like and the content of the package?**
Lynparza 100 mg tablets are yellow to dark yellow, oval, bi-convex, film-coated tablets, marked with “OP100” on one side and plain on the other.
Lynparza 150 mg tablets are green to green/grey, oval, bi-convex, film-coated tablets, marked with “OP150” on one side and plain on the other.
Lynparza is supplied in packs containing 56 film-coated tablets (7 blisters of 8 tablets each), or multipacks containing 112 (2 packs of 56) film-coated tablets.
Not all pack sizes may be marketed.

Manufacturer:

AstraZeneca UK limited Silk Road Business Park, Macclesfield, Cheshire SK10 2NA, UK

License Holder:

AstraZeneca (Israel) Ltd.,

1 Atirei Yeda St.,
Kfar Saba 4464301

Registration number of the medicine in the National Drug Registry of the Ministry of Health:

Lynparza 100 mg - 161-63-35469

Lynparza 150 mg - 161-64-35470

Revised in January 2022 according to the MoH guidelines.